Company Profile
BioNTech Stock Price, News & Analysis
- Ticker:
- BNTX
- Exchange:
- NASDAQ
- Sector:
- Nucleic Acid Drugs
- Location:
- Mainz, Germany
Stock performance
91.19 USD (-1.07%)
Close
Last updated: August 6, 2026
22.5B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BNTX closed down 1.07% at $91.19. No new same-company headline was identified in the current news window.
Company overview
Next-Generation Biopharmaceutical Platform
BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor types.
Pumitamig
Pumitamig, also known as BNT327 or BMS986545, is a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization. BioNTech and Bristol Myers Squibb are evaluating it in a broad pivotal program spanning lung, breast, colorectal, gastric and other solid tumors.
Gotistobart
Gotistobart is a tumor-microenvironment-selective CTLA-4 antibody designed to deplete regulatory T cells. The Phase 3 PRESERVE-003 trial is evaluating it in metastatic squamous non-small cell lung cancer after platinum chemotherapy and PD-(L)1 treatment.
HER2-Targeted ADC
Trastuzumab pamirtecan is a HER2-targeted antibody-drug conjugate partnered with DualityBio. It is being developed in recurrent endometrial cancer and HER2-low metastatic breast cancer through potentially registrational cohorts and Phase 3 trials.
B7H3-Targeted ADC
BNT324, or DB-1311, is a B7H3-targeted antibody-drug conjugate with clinical activity under evaluation in prostate, cervical and ovarian cancers. A Phase 3 trial against docetaxel in metastatic castration-resistant prostate cancer is planned.
Infectious-Disease Vaccines
BioNTech’s commercial vaccine business remains anchored by its COVID-19 collaboration with Pfizer. The partners continue to adapt the vaccine to circulating variants and prepare for seasonal regulatory approvals and supply.
Future catalysts
Phase 2 data from the ROSETTA Lung-02 pumitamig trial at ASCO on May 29–June 2, 2026.
Multiple pumitamig combination readouts expected during 2026.
Interim pivotal-stage data from the Phase 3 PRESERVE-003 gotistobart trial expected in 2026.
BLA submission for trastuzumab pamirtecan in endometrial cancer planned in 2026, subject to regulatory feedback.
Phase 3 DYNASTY-Breast02 data for trastuzumab pamirtecan expected in 2026.
Initiation of the Phase 3 BNT324 trial in metastatic castration-resistant prostate cancer expected in 2026.
Potential launch of a variant-adapted COVID-19 vaccine ahead of the 2026/2027 vaccination season, pending approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioNTech (BNTX)?
BioNTech (BNTX) most recently closed at 91.19 USD, a -1.07% move versus the previous session.
What is the market cap of BioNTech (BNTX)?
BioNTech currently has a market capitalization of 22.5B USD on BioPharmSignal.
What does BioNTech do?
Next-Generation Biopharmaceutical Platform BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor types. Pumitamig Pumitamig,...
On which exchange is BNTX stock listed?
BioNTech (BNTX) is associated with NASDAQ, Mainz, Germany, Nucleic Acid Drugs.
What is PD-L1?
Pumitamig Pumitamig, also known as BNT327 or BMS986545, is a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization.
Which conditions is BioNTech targeting with PD-L1?
BioNTech is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does BioNTech describe recent progress with PD-L1?
Phase 2 data from the ROSETTA Lung-02 pumitamig trial at ASCO on May 29–June 2, 2026. Multiple pumitamig combination readouts expected during 2026. Interim pivotal-stage data from the Phase 3 PRESERVE-003 gotistobart trial expected in 2026. BLA submission for trastuzumab pamirtecan in endometrial cancer planned in 2026, subject to regulatory feedback. Phase...
What is VEGF-A?
Pumitamig Pumitamig, also known as BNT327 or BMS986545, is a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization.